From: The Aplidin analogs PM01215 and PM02781 inhibit angiogenesis in vitro and in vivo
HUVEC (n = 3) | Untreated 11.0 ± 0.6 | ||||
---|---|---|---|---|---|
concentration [nM] | bortezomib | Aplidin™ | PM01215 | PM 02781 | |
10 | 45.0 ± 14.0* | 10.7 ± 1.3 | 10.3 ± 0.9 | 11.0 ± 0.6 | |
50 | 68.0 ± 11.2* | 22.7 ± 2.6* | 12.0 ± 0.0 | 12.7 ± 0.9 | |
100 | 73.0 ± 10.8* | 34.3 ± 2.7* | 17.3 ± 0.3* | 23.0 ± 2.6* | |
200 | 78.3 ± 11.5* | 56.0 ± 4.5* | 31.0 ± 4.0* | 44.3 ± 10. 7* | |
HDFs (n = 3) | Untreated 5.3 ± 0.3 | ||||
concentration [nM] | bortezomib | Aplidin™ | PM01215 | PM 02781 | |
10 | 4.7 ± 0.3 | 4.3 ± 0.3 | 4.7 ± 0.7 | 4.7 ± 0.3 | |
50 | 7.7 ± 0.7 | 5.3 ± 0.7 | 4.3 ± 0.3 | 4.7 ± 0.3 | |
100 | 10.3 ± 0.7* | 9.0 ± 0.4 | 4.3 ± 0.3 | 6.3 ± 0.3 | |
200 | 12.7 ± 1.7* | 12.3 ± 0.7* | 6.0 ± 1.0 | 7.3 ± 1.2 | |
PBMNC (n = 3) | Untreated 11.3 ± 0.9 | ||||
concentration [nM] | bortezomib | Aplidin™ | PM01215 | PM 02781 | |
10 | 9.7 ± 2.3 | 10.3 ± 1.2 | 9.7 ± 0.9 | 10.0 ± 1.5 | |
50 | 25.0 ± 1.0* | 11.7 ± 1.3 | 9.7 ± 1.3 | 10.0 ± 1.2 | |
100 | 28.0 ± 2.0* | 12.3 ± 1.7 | 9.7 ± 1.3 | 11.7 ± 2.3 | |
200 | 29.7 ± 2.3* | 19.3 ± 1.7* | 11.0 ± 1.5 | 12.7 ± 1.9 |